prt7732
·Code: PRT7732
prt7732: developed by 1 company · 1 clinical trial tracked.
prt7732 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect prt7732 to PRLD; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could prt7732 → PRLD affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Advanced Solid TumorEsophageal Squamous Cell Carcinoma
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Prelude Therapeutics Inc (PRLD) Advanced Solid Tumor | Phase 1 |
Clinical Trials (1)
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4
Primary endpoint: Dose Limiting toxicity (DLT) of PRT7732
Interventionalopen42 targetStarted 2024-11Completion 2026-0128 sites · Australia, Germany, Japan, South Korea…Prelude Therapeutics
Frequently asked questions
Who is developing prt7732?
prt7732 is being developed by Prelude Therapeutics Inc.
How many clinical trials involve prt7732?
BioSniper tracks 1 clinical trial involving prt7732.